Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

PNU-159548 undergoes phase I trials; preclinical results presented at AACR meeting

April 22, 1999

Efficacy of IL-2 Gene Medicine is enhanced by combination with chemotherapeutic agent

April 22, 1999

GnRH pharmaccine reduces testosterone to castration levels

April 22, 1999

Small peptide from Angstrom highly active against human breast tumor xenografts

April 21, 1999

Sanofi and Lilly to jointly develop oxaliplatin in U.S.

April 21, 1999

SQ-885: a specific angiogenesis inhibitor and integrin antagonist

April 21, 1999

Immunomedics clones RNase and prepares RNase-containing anticancer fusion protein

April 21, 1999

Targretin as novel therapy for refractory breast cancer: preclinical studies

April 21, 1999

Encore begins phase II trials in prostate cancer patients of its lead product

April 21, 1999

Selective inhibitors of VEGF and FGF tyrosine kinase reported by Zeneca

April 21, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.